Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $41.5052W HIGH $166.47
Volume
1.31 M
Value Traded
103.73 M
Short % Float
20.39%
-7.43%Week
+71.15%1 Month
+84.18%3 Month
+190.62%6 Month
+381.65%5 Year
+381.65%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.92 B
EPS (TTM)
-8.77
P/E Ratio
-
Ent. Value
5.06 B
Total Shares
44.67 M
Float Shares
42.00 M
Insiders
5.96%
Institutions
85.85%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
GRAL Catalyst Timeline
Dated clinical, regulatory and corporate events for GRAIL, Inc.
Past FDA Catalysts and PDUFA Decisions
How GRAL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
GRAIL, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every GRAL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Galleri Breakthrough | Multi-Cancer Early Detection | 2026-05-31 | 6.5-fold increase in cancer detection; 71% of newly detected cancers were in early stages I-III; 60% of diagnosed cancers were screen-detected (264/440); 60.3% positive predictive value (PPV)Read More | GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Freidin AaronOfficer (Chief Financial Officer) | Sell | -23,619 225,364 held | $146.39 | 10/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GRAL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 1.4 % (16.7 %) | 275.03 M | 4.03 M |
GRAL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GRAL ranks across every disease it competes in
Competitive Position is a premium feature
See how GRAL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGRAL News
GRAL▼ -10.9%on this news
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026
GRAIL, Inc. will present new data from the NHS-Galleri trial and PATHFINDER 2 study at the Early Detection of Cancer Conference and ESMO Congress 2026. The presentations will cover various aspects of the Galleri multi-cancer early detection test, including its efficiency, safety, and performance across different demographics. The findings aim to reinforce the integration of multi-cancer early detection into routine healthcare.
Read more →GRAL▲ +15.4%on this news· ran to +26% by day 3
FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test
GRAIL, Inc. announced a favorable vote from the FDA's advisory committee for its Galleri multi-cancer early detection test. The committee voted that the benefits of Galleri outweigh its risks, supporting its safety and effectiveness. The Galleri test aims to enhance cancer screening by detecting multiple cancers early, potentially improving treatment outcomes.
Read more →GRALGRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GRAIL, Inc. has granted equity awards in the form of restricted stock units to 59 new non-executive employees as part of its inducement plan under Nasdaq Listing Rule 5635(c)(4). The awards, totaling 55,867 shares, are designed to attract new talent to the company. The RSUs will vest over four years, promoting long-term commitment from the new hires.
Read more →GRALGRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference
GRAIL, Inc. will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. The presentation will focus on the company's mission to detect cancer early using advanced technologies. A live webcast of the event will be available, along with a replay for 30 days. GRAIL aims to alleviate the global burden of cancer through innovative detection methods.
Read more →GRAL▲ +6.9%on this news
GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
GRAIL, Inc. announced that the FDA's Advisory Committee will review its Premarket Approval application for the Galleri multi-cancer early detection test on September 23, 2026. The test aims to identify cancer-specific methylation patterns before symptoms arise, enhancing early detection. GRAIL's CEO emphasized the need for improved cancer screening methods, citing significant data supporting Galleri's efficacy.
Read more →GRAL▼ -14.5%on this newsshared move
GRAIL Reports Second Quarter 2026 Financial Results
GRAIL, Inc. reported a 26% increase in total revenue for Q2 2026, reaching $44.7 million, driven by a 24% rise in Galleri test revenue. The company presented promising results from the NHS-Galleri and PATHFINDER 2 studies at the ASCO Annual Meeting, showcasing the clinical utility of Galleri. Despite a net loss of $110.2 million, GRAIL completed a $110 million equity financing with Samsung to expand its market presence.
Read more →GRALGRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference
GRAIL, Inc. will present at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. The presentation will focus on their mission to detect cancer early using advanced technologies. Live webcasts will be available on their investor relations website, with recordings accessible for 30 days post-event.
Read more →GRAL▲ +12.1%on this newsshared move
GRAIL to Announce Second Quarter 2026 Financial Results
GRAIL, Inc. will announce its financial results for the second quarter of 2026 on August 5, 2026. Following the announcement, a conference call and webcast will be held to discuss the results and business developments. The event is open to all interested parties, and registration is encouraged for timely connection.
Read more →GRALEHE Health Announces Access to GRAIL's Galleri® Test
EHE Health has partnered with GRAIL to provide the Galleri multi-cancer early detection test to select members. This initiative aims to improve early cancer detection, particularly for cancers lacking recommended screening options. Eligible members can access the test at a discounted price following their EHE exam. The Galleri test boasts over 90% accuracy in predicting cancer signals.
Read more →GRALPriority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri® Multi-Cancer Early Detection Blood Test to Employer Plans
GRAIL, Inc. has partnered with Priority Health to offer the Galleri multi-cancer early detection test to employer groups in Michigan. This collaboration aims to enhance cancer screening options and promote early detection, which can lead to better patient outcomes. Priority Health previously launched coverage for Galleri in its Medicare Advantage plans and is now expanding this offering.
Read more →GRALGRAIL Completes $110 Million Equity Financing With Samsung Entities
GRAIL, Inc. has successfully closed a $110 million equity financing round with Samsung affiliates, which will aid in its mission to enhance early cancer detection. The investment will help GRAIL secure regulatory approvals and expand its Galleri test internationally, particularly in South Korea and potentially other Asian markets. This partnership is seen as a significant step towards improving cancer care through innovative screening technologies.
Read more →GRAL▲ +5.7%on this newsshared move
Welcome to the Superaging Era: Youth is no Longer the Holy Grail as Gen X and Millennials Chase the 100-Year Lifestyle
New research from Havas Health reveals a cultural shift in how society perceives aging, emphasizing vitality and quality of life over chronological age. The report, titled 'Superaging', highlights the emergence of a $33 trillion longevity economy, driven by proactive consumer attitudes towards aging. This shift is reshaping industries and consumer behavior, indicating a significant change in societal values regarding age.
Read more →GRAL▼ -10.2%on this news
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
GRAIL, Inc. announced positive results from its PATHFINDER 2 study, which involved 35,878 participants. The Galleri Multi-Cancer Early Detection Test demonstrated a 6.5-fold increase in cancer detection when combined with standard screenings for various cancers. Notably, 71% of the newly detected cancers were in early stages I-III, indicating the test's effectiveness in early diagnosis.
Read more →GRAL▼ -10.2%on this newsshared move
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
GRAIL, Inc. presented results from the NHS-Galleri trial at the 2026 ASCO Annual Meeting, highlighting the Galleri blood test's effectiveness in reducing Stage IV cancer diagnoses. The test demonstrated a 22% reduction in the second screening round and a 26% reduction in the third. Additionally, it increased the cancer detection rate significantly when used alongside standard care.
Read more →GRALGRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted...
GRAIL, Inc. recently announced the granting of equity awards, specifically restricted stock units (RSUs), to 56 new non-executive employees. This initiative is part of their Inducement Equity Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4). The RSUs, totaling 34,350 shares, will vest over four years, encouraging long-term employment. This move reflects GRAIL's commitment to expanding its workforce while focusing on its mission to detect cancer early.
Read more →GRALGRAIL to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
GRAIL, Inc. will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The presentation will focus on the company's mission to detect cancer early using advanced technologies. Live and replay webcasts will be available on GRAIL's investor relations website. The company aims to alleviate the global burden of cancer through innovative solutions.
Read more →GRALGRAIL to Present at the 2026 Jefferies Global Healthcare Conference
GRAIL, Inc. announced that its management will present at the 2026 Jefferies Global Healthcare Conference on June 3 at 7:35 a.m. ET. The company is dedicated to early cancer detection, utilizing advanced technologies to improve patient outcomes. The event will be accessible via live and archived webcasts on GRAIL's investor relations website.
Read more →GRAL▲ +15.3%on this news
GRAIL Reports First Quarter 2026 Financial Results
GRAIL, Inc. reported a strong financial performance for Q1 2026, with a 37% increase in Galleri revenue and a 50% rise in test volume. The company announced a partnership with Epic to integrate the Galleri test into their electronic health record platform, aiming to improve nationwide access. Despite these positive developments, GRAIL reported a significant net loss of $93.2 million for the quarter.
Read more →GRAL▲ +9.6%on this newsshared move
GRAIL to Present at the BofA Securities 2026 Health Care Conference GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company...
GRAIL, Inc. has announced its presentation at the BofA Securities 2026 Health Care Conference scheduled for May 12 in Las Vegas. The company's management will discuss its mission of early cancer detection, a critical area that can significantly improve treatment outcomes. Investors can access live and replay webcasts of the presentation through GRAIL's investor relations website. This event will enhance GRAIL's presence within the healthcare community and among potential investors.
Read more →GRALGRAIL to Announce First Quarter 2026 Financial Results
GRAIL, Inc. announced it will release its financial results for the first quarter of 2026 on May 5, 2026. Following the release, a webcast and conference call will be held to discuss the results and business progress. GRAIL focuses on early cancer detection using advanced technologies.
Read more →About GRAIL, Inc.
Headquarters1525 O'BRIEN DRIVE, MENLO PARK, CA, 94025
BIOPHARMAWATCH ELITE PLUS
Trade the next GRAL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime